News

Vaxxel SAS, a French start-up, developing vaccines against respiratory viral infections, announces the acquisition of Transgene’s proprietary DuckCelt-T17 cell line. The terms of the…
Read More...

Junshi Biosciences and Eli Lilly and Company announced they have entered into an agreement to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19,…
Read More...

Menarini Group, a privately held Italian pharmaceutical and diagnostics company, and Stemline Therapeutics Inc., a commercial-stage biopharmaceutical company focused on the development…
Read More...

INOVIO announced it has entered into an agreement to expand its manufacturing partnership with the German contract manufacturer Richter-Helm BioLogics GmbH & Co. KG, to support…
Read More...

Moderna, Inc. a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and…
Read More...

AstraZeneca and the University of Oxford announced an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at…
Read More...

WuXi Biologics and Aravive, Inc. announced a strategic collaboration agreement granting Aravive the right to use the proprietary WuXiBody platform to develop high-affinity bispecific…
Read More...

Trio Pharmaceuticals, Inc. ("TRIO"), a cancer therapeutics company developing novel dual action antibody drugs, TRIObody, and novel dual action antibody drug conjugates, TRIObody Drug…
Read More...

Novartis announced plans to initiate a Phase III clinical trial to study canakinumab in patients with COVID-19 pneumonia. The CAN-COVID trial will examine the efficacy of utilizing…
Read More...

BioDuro, LLC, a leading drug discovery and development services organization, and neoX, a leading-edge artificial intelligence and biophysics focused biotech, announced a strategic…
Read More...

The University of Queensland’s COVID-19 vaccine has passed another important milestone, showing the ability to raise high levels of antibodies that can neutralise the virus in early…
Read More...

Gilead Sciences, Inc. announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in…
Read More...

Atreca, Inc. BeiGene, Ltd. and IGM Biosciences, Inc. announced their plans to collaborate to help address the COVID-19 pandemic. The companies will leverage their combined technology…
Read More...

GlaxoSmithKline plc announced the US Food and Drug Administration (FDA) approved the company’s supplemental New Drug Application (sNDA) for Zejula (niraparib), an oral, once-daily poly…
Read More...

Catalent, Inc. announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent’s Biologics business unit will accelerate availability of…
Read More...

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced by Quotient Sciences and CytoAgents, Inc. The partnership will…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an additional recommended dosage of 400 mg every six…
Read More...

Q2Earth, Inc. announced that its wholly-owned subsidiary, QSAM Therapeutics Inc. has signed a Patent and Technology License Agreement and Trademark Assignment with IGL Pharma, Inc.…
Read More...

Pneumagen Ltd, a University of St Andrews spinout, focused on treating infectious disease and oncology by targeting the human glycome, today announced results from three separate in…
Read More...

Kamada Ltd. and Kedrion Biopharma, two prominent bio-pharmaceutical companies specialized in plasma-derived protein therapeutics, announced a global collaboration for the development,…
Read More...